CD10 is expressed in a subset of chromophobe renal cell carcinomas

Abstract

CD10 has been considered a useful marker in the diagnosis of renal carcinomas, because of its expression in clear cell and papillary renal cell carcinomas and its absence in chromophobe renal cell carcinomas. On the other hand, chromophobe renal cell carcinoma expresses parvalbumin, which is absent in clear cell and papillary renal cell carcinomas. To further address the relevance of these markers, we studied the expression of CD10 and parvalbumin in 42 samples of chromophobe renal cell carcinoma (seven of which had aggressive features, including invasion beyond the renal capsule, renal vein invasion, metastases, or sarcomatoid transformation), 75 clear cell renal cell carcinomas (eight metastatic) and 51 papillary renal cell carcinomas (two metastatic). CD10 was found in 100% of clear cell renal cell carcinomas, 63% of papillary renal cell carcinomas and in all metastatic cases of both types. At variance with previous studies, we found CD10 expression in from 30 to 90% of the neoplastic cells, in 11 of 42 (26%) chromophobe renal cell carcinomas. The CD10-positive cases included five of the seven (71%) chromophobe renal cell carcinoma with aggressive features. Statistical analysis showed significant association of CD10-positive tumors with clinicopathologic aggressiveness (P ¼ 0.003) and mitotic figures (P ¼ 0.04). Parvalbumin was strongly expressed in all primary and metastatic chromophobe renal cell carcinomas. Western blot analysis was utilized to confirm the expression of both CD10 and parvalbumin in chromophobe renal cell carcinomas. Keywords: chromophobe renal cell carcinoma; renal cell carcinoma; immunohistochemistry; CD10; parvalbumin The importance of distinguishing the different types of renal cell carcinoma is underscored by the fact that they have different prognoses. 1-3 CD10, a cell surface metalloproteinase localized to the proximal nephron of the normal adult kidney, 4 has been proposed as a useful tool in the differential diagnosis of renal epithelial neoplasms. [5][6][7] This molecule has been described as a positive immunohistochemical marker for the two most common types of kidney cancer, clear cell and papillary renal cell carcinomas. [5][6][7][8][9] Previous studies analyzing CD10 immunoreactivity in a total of 25 chromophobe renal cell carcinomas have found negative reactions, 5,7 whereas Holm-Nielsen et al 10 found CD10 expressed in all three chromophobe carcinomas studied and Higgins et al 11 found a positive reaction in one of three tumors tested. In this study we undertook to investigate CD10 and parvalbumin immunoreactivity in a large series of clear cell, papillary, and chromophobe renal cell carcinomas. Materials and methods Patients and Tissue SamplesWe studied the immunohistochemical expression of CD10 and parvalbumin in 75 clear cell renal cell carcinomas, 51 papillary renal cell carcinomas and 38 chromophobe renal cell carcinomas (including 36

Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma

“…[39][40][41][42][43][44] The histochemical and immunohistochemical analyses showed results as expected, regarding the epithelial component. 23,45,46 Parvalbumin and CK7 showed immunoexpression in the chromophobic cells whereas vimentin was absent; Hale's colloidal iron stain was diffusely positive. Moreover sarcomatoid component of chromophobe renal cell carcinomas displayed a patchy staining with Hale's colloidal iron and did not for parvalbumin and CK7.…”

“…Seven cases have been reported previously. 20,23 For all formalin-fixed and paraffin-embedded tumors, serial 5 mm sections were stained with hematoxylin and eosin, with Hale's colloidal iron technique and immunostained with antibodies recognizing the following markers: parvalbumin (PA-235, Sigma Chemical Company, St Louis, MO, USA; dilution, 1:500), cytokeratin 7 (protease, 1:50; DAKO, Carpinteria, CA, USA) and vimentin (steam, 1:100; Zymed, San Francisco, CA, USA). Immunoreactions were developed using a non-biotin, highly sensitive system (Envision peroxidase detection system, DAKO, Carpinteria, CA, USA) preventing possible false-positive staining due to endogenous biotin present in the tissues.…”

“…2 Chromophobe renal cell carcinomas with distant metastases or sarcomatoid transformation are uncommon. [3][4][5][6] Most have been reported as single cases [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] and few cytogenetic data are available. 24 We sought to identify cytogenetic characteristics of sarcomatoid and metastatic chromophobe renal cell carcinomas by interphase fluorescence in situ hybridization (FISH) analysis.…”

Diagnostic utility of S100A1 expression in renal cell neoplasms: an immunohistochemical and quantitative RT-PCR study

“…[8][9][10] Numerous immunohistochemical markers have been proposed for the subclassification of renal cell carcinomas, including 'RCC marker', CD10, and vimentin for clear cell renal cell carcinomas, c-kit for chromophobe renal cell carcinomas, and cytokeratin 7 and alpha-methyl-acyl-CoA racemase for papillary renal cell carcinomas. 8,9,11,12 Parvalbumin, a calcium-binding protein, has been demonstrated to be a useful marker in distinguishing oncocytoma and chromophobe renal cell carcinoma, from clear cell and papillary renal cell carcinomas.…”

Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma

“…72,84 Because of its frequent and somewhat restricted expression in the latter tumors, CD10 is often regarded as a renal cell carcinoma-associated marker, even though it is not specific for these tumors. CD10 is expressed in all subtypes of renal cell carcinomas, including clear cell (B80-100%), 10,72,77,78,[84][85][86] papillary (B65-100%), 41,72,77,78,[84][85][86][87] and chromophobe (B40-65%). 10,77,78,85,88 Only a few studies have been published on the expression of CD10 in mesotheliomas.…”